AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02454400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list
Description: Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active
Study NCT03647033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent implantation
Description: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
Study NCT00817024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,
Description: 3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Study NCT00817024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules
Description: 3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
Study NCT00817024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules
Description: 3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Study NCT02716571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis or Plasmapheresis
Description: Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE).
Study NCT00577681 — intervention group
Intervention type: DRUG
Intervention: Antiretroviral Therapy (ART)
Description: Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
Study NCT02563405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
Study NCT02563405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
Study NCT04245787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self assembling peptide with fluoride
Description: peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
Study NCT04245787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self assembling peptide with fluoride
Description: peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
Study NCT01025791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Study NCT03249909 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber
Description: gelling fibre without silver
Study NCT03249909 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aquacel Ag Extra
Description: gelling fibre with silver
Study NCT00873041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Supplied as 125 mg, 250 mg and 500 mg tablets.
Study NCT00873041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.
Study NCT00873041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.
Study NCT02998411 — intervention group
Intervention type: OTHER
Intervention: Titration
Study NCT02746887 — intervention group
Intervention type: OTHER
Intervention: Preterm/term cohort
Study NCT04630860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glyburide
Description: Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
Study NCT00313313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
Study NCT02601235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naridrin
Description: Naridrin® : 2 drops in each nostril once daily as prescription
Study NCT02601235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrin
Description: 2 pumps in each nostril every 12 hours.
Study NCT03392831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripherally inserted central catheter (PICC)
Description: The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
Study NCT03392831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheter
Description: The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
Study NCT02427386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dynamized estrogen
Description: The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
Study NCT02427386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
Study NCT02694276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
Study NCT02293252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (Motiva)
Description: interactive bi-directional home telemonitoring system that provides remote monitoring
Study NCT02527226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial exercises
Description: A series of self-administered facial movements and expressions.
Study NCT02119195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sealant
Description: resin-based sealant (Clinpro Sealant, 3M ESPE)
Study NCT03737448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Subjects with receive up to 60 mg daily
Study NCT04493541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified Dose on Specified Days
Study NCT04493541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986256 Placebo
Description: Specified Dose on Specified Days
Study NCT04678037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROs assessment using sickle cell disease mobile app (SCD-app)
Description: A smartphone app platform designed for patients with sickle cell disease. The SCD-app is programmed to send notification to patients to complete PROs assessment. The SCD-app is able to collect PROs data as patients complete the assessment using the app platform.
Study NCT02182024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high dose
Study NCT02182024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low dose
Study NCT02872025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Injected intralesionally
Study NCT02872025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intralesional mRNA 2752
Description: Injected intralesionally
Study NCT01025791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Study NCT02692768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Music Therapy
Description: Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
Study NCT02692768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recorded Music Therapy
Description: Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
Study NCT02692768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
Study NCT01003756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative neuromuscular exercise
Description: A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
Study NCT03295227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04039841 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Motor Imagery Test
Description: Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential.
Study NCT03661359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Determinants of Health Referrals
Description: Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
Study NCT03449940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate repair
Study NCT03449940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed repair
Study NCT03449940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
Study NCT03449940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
Study NCT03449940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
Study NCT02621541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Study NCT04037449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
Study NCT04037449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional analgesia
Description: Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)
Study NCT01731158 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Avastin in combination with Roferon-A
Study NCT01731158 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afinitor
Study NCT01731158 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TKI: Sutent, Nexavar or Votrient
Description: TKI
Study NCT01234454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
Study NCT01234454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
Study NCT01296893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
Study NCT05435807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Neuroscience Education
Description: Therapeutic Neuroscience Education (TNE) is an intervention used by physiotherapists, which can be defined as a cognitive behavioral therapy method. By helping patients better understand the biological process that underlies their painful condition, it aims to achieve therapeutic effects such as reducing pain and the fear associated with musculoskeletal injuries and increasing movement and functionality.
Study NCT02274480 — intervention group
Intervention type: DEVICE
Intervention: cardiac MRI with DWI
Study NCT01650649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
Study NCT01025791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 1.0 mg
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study NCT00469144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%.
Study NCT00469144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
Study NCT04051034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Active: 1.25 g capsules/420 35-count bottles \[1.25 g capsule contains min. 750 mg EPA + 250 mg DHA\] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles \[1.25-gram high oleic safflower oil capsule\]
Study NCT04051034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active: 1.25 g capsules \[1.25-gram high oleic safflower oil capsule\] and heat therapy, increase internal body temperature 1.2 C above baseline.
Study NCT00869336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1% - 2 wks
Description: Topical cream applied daily for 2 weeks
Study NCT00869336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator -2 wks
Description: Placebo cream applied daily for 2 weeks
Study NCT00869336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1% - 4 wks
Description: Topical cream applied daily for 4 weeks
Study NCT00869336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator - 4 wks
Description: Placebo cream applied daily for 4 weeks
Study NCT03471000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short implants Treatment
Description: Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
Study NCT03471000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular implants Treatment
Description: Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
Study NCT03764098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine ER
Description: Guanfacine Extended Release (6mg/day ER)
Study NCT03764098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo